{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:26:55Z","timestamp":1792985215421,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Zhejiang Pharmaceutical Society Hospital Pharmacy Special Research Grant Project","award":["2022ZYY03"],"award-info":[{"award-number":["2022ZYY03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Inform Decis Mak"],"DOI":"10.1186\/s12911-024-02694-x","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T09:01:57Z","timestamp":1728032517000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Machine learning\u2013based prediction model for hypofibrinogenemia after tigecycline therapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Jianping","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liucheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayue","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"issue":"3","key":"2694_CR1","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268\u201381.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"2694_CR2","first-page":"277","volume":"40","author":"CL Ventola","year":"2015","unstructured":"Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P t. 2015;40(4):277\u201383.","journal-title":"P t"},{"key":"2694_CR3","doi-asserted-by":"crossref","unstructured":"Rusu A, Buta EL. The Development of Third-Generation Tetracycline antibiotics and New perspectives. Pharmaceutics 2021; 13(12).","DOI":"10.3390\/pharmaceutics13122085"},{"issue":"7","key":"2694_CR4","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s10096-020-04121-1","volume":"41","author":"S Yaghoubi","year":"2022","unstructured":"Yaghoubi S, Zekiy AO, Krutova M, et al. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. Eur J Clin Microbiol Infect Dis. 2022;41(7):1003\u201322.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"2694_CR5","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s13318-022-00789-2","volume":"47","author":"C Dorn","year":"2022","unstructured":"Dorn C, Petroff D, Kratzer A, et al. Tigecycline Soft Tissue Penetration in obese and non-obese Surgical patients determined by using in Vivo Microdialysis. Eur J Drug Metab Pharmacokinet. 2022;47(5):749\u201355.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2694_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijid.2018.08.007","volume":"75","author":"Y Song","year":"2018","unstructured":"Song Y, Hu L, Shu Q, et al. Tigecycline salvage therapy for critically ill children with multidrug-resistant\/extensively drug-resistant infections after surgery. Int J Infect Dis. 2018;75:82\u20138.","journal-title":"Int J Infect Dis"},{"issue":"6","key":"2694_CR7","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1248\/bpb.35.967","volume":"35","author":"K Kadoyama","year":"2012","unstructured":"Kadoyama K, Sakaeda T, Tamon A, et al. Adverse event profile of tigecycline: data mining of the public version of the U.S. Food and Drug Administration adverse event reporting system. Biol Pharm Bull. 2012;35(6):967\u201370.","journal-title":"Biol Pharm Bull"},{"issue":"10","key":"2694_CR8","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.21037\/tau-22-522","volume":"11","author":"W Xie","year":"2022","unstructured":"Xie W, Ma K, Xu Z, et al. Risk factors of tigecycline-associated fibrinogen reduction in patients with renal transplantation: a case-control study. Transl Androl Urol. 2022;11(10):1410\u20138.","journal-title":"Transl Androl Urol"},{"issue":"43","key":"2694_CR9","doi-asserted-by":"publisher","first-page":"e22638","DOI":"10.1097\/MD.0000000000022638","volume":"99","author":"Q Fan","year":"2020","unstructured":"Fan Q, Huang W, Weng Y, et al. Hypofibrinogenemia induced by high-dose tigecycline-case report and review of literature. Med (Baltim). 2020;99(43):e22638.","journal-title":"Med (Baltim)"},{"issue":"9\u201310","key":"2694_CR10","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1159\/000525380","volume":"107","author":"D Wang","year":"2022","unstructured":"Wang D, Lin C, Gu C, et al. Tigecycline-Associated Coagulopathy: a single-Center Retrospective Analysis. Pharmacology. 2022;107(9\u201310):524\u201336.","journal-title":"Pharmacology"},{"issue":"6","key":"2694_CR11","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1111\/jcpt.13250","volume":"45","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Wang J, Liu H, et al. Risk factors for tigecycline-induced hypofibrinogenaemia. J Clin Pharm Ther. 2020;45(6):1434\u201341.","journal-title":"J Clin Pharm Ther"},{"key":"2694_CR12","doi-asserted-by":"crossref","unstructured":"Kryczka KE, Kruk M, Demkow M et al. Fibrinogen and a Triad of Thrombosis, Inflammation, and the Renin-Angiotensin System in Premature Coronary Artery Disease in Women: A New Insight into Sex-Related Differences in the Pathogenesis of the Disease. Biomolecules. 2021; 11(7).","DOI":"10.3390\/biom11071036"},{"key":"2694_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2147\/TCRM.S302850","volume":"17","author":"J Liu","year":"2021","unstructured":"Liu J, Yan Y, Zhang F. Risk factors for Tigecycline-Associated Hypofibrinogenemia. Ther Clin Risk Manag. 2021;17:325\u201332.","journal-title":"Ther Clin Risk Manag"},{"issue":"7","key":"2694_CR14","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00228-020-02860-w","volume":"76","author":"J Hu","year":"2020","unstructured":"Hu J, Xiao YH, Zheng Y, et al. Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients. Eur J Clin Pharmacol. 2020;76(7):913\u201322.","journal-title":"Eur J Clin Pharmacol"},{"issue":"49","key":"2694_CR15","doi-asserted-by":"publisher","first-page":"e9124","DOI":"10.1097\/MD.0000000000009124","volume":"96","author":"X Wu","year":"2017","unstructured":"Wu X, Zhao P, Dong L, et al. A case report of patient with severe acute cholangitis with tigecycline treatment causing coagulopathy and hypofibrinogenemia. Med (Baltim). 2017;96(49):e9124.","journal-title":"Med (Baltim)"},{"issue":"3","key":"2694_CR16","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1128\/AAC.04305-14","volume":"59","author":"Q Zhang","year":"2015","unstructured":"Zhang Q, Zhou S, Zhou J. Tigecycline treatment causes a decrease in fibrinogen levels. Antimicrob Agents Chemother. 2015;59(3):1650\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"2694_CR17","doi-asserted-by":"crossref","unstructured":"Frazier, PIJapa. A tutorial on Bayesian optimization. 2018.","DOI":"10.1287\/educ.2018.0188"},{"key":"2694_CR18","doi-asserted-by":"crossref","unstructured":"Ma WJJN. Bayesian decision models: A primer. 2019; 104(1): pp. 164\u2013175.","DOI":"10.1016\/j.neuron.2019.09.037"},{"key":"2694_CR19","doi-asserted-by":"crossref","unstructured":"Gao L, Ding, YJBrn. Disease prediction via bayesian hyperparameter optimization and ensemble learning. 2020; 13: pp. 1\u20136.","DOI":"10.1186\/s13104-020-05050-0"},{"issue":"Suppl 2","key":"2694_CR20","doi-asserted-by":"publisher","first-page":"ii37","DOI":"10.1093\/jac\/dkt143","volume":"68","author":"X Guirao","year":"2013","unstructured":"Guirao X, S\u00e1nchez Garc\u00eda M, Bassetti M, et al. Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies. J Antimicrob Chemother. 2013;68(Suppl 2):ii37\u201344.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2694_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12959-022-00369-z","volume":"20","author":"M Guo","year":"2022","unstructured":"Guo M, Liang J, Li D, et al. Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database. Thromb J. 2022;20(1):12.","journal-title":"Thromb J"},{"issue":"10","key":"2694_CR22","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00277-010-0911-7","volume":"89","author":"H Pieringer","year":"2010","unstructured":"Pieringer H, Schmekal B, Biesenbach G, et al. Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline. Ann Hematol. 2010;89(10):1063\u20134.","journal-title":"Ann Hematol"},{"issue":"6","key":"2694_CR23","first-page":"915","volume":"19","author":"Q Zhang","year":"2015","unstructured":"Zhang Q, Zhou J. Fibrinogenopenia caused by Tigecycline: a case report. Eur Rev Med Pharmacol Sci. 2015;19(6):915\u20137.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2694_CR24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.idcr.2018.01.003","volume":"11","author":"PC Wu","year":"2018","unstructured":"Wu PC, Wu CC. Tigecycline-associated hypofibrinogenemia: a case report and review of the literature. IDCases. 2018;11:56\u20137.","journal-title":"IDCases"},{"issue":"10","key":"2694_CR25","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3109\/23744235.2015.1043942","volume":"47","author":"N Sabanis","year":"2015","unstructured":"Sabanis N, Paschou E, Gavriilaki E, et al. Hypofibrinogenemia induced by tigecycline: a potentially life-threatening coagulation disorder. Infect Dis. 2015;47(10):743\u20136.","journal-title":"Infect Dis"},{"issue":"1","key":"2694_CR26","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1080\/10408347.2020.1793098","volume":"52","author":"M Bialkower","year":"2022","unstructured":"Bialkower M, Garnier G. Fibrinogen Diagnostics in Major Hemorrhage. Crit Rev Anal Chem. 2022;52(1):194\u2013209.","journal-title":"Crit Rev Anal Chem"},{"issue":"1","key":"2694_CR27","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1186\/s12879-021-06420-0","volume":"21","author":"L Zhu","year":"2021","unstructured":"Zhu L, Wang L, Zhang Y, et al. Fatal hemorrhagic pneumonia in patients with hematologic diseases and Stenotrophomonas maltophilia bacteremia: a retrospective study. BMC Infect Dis. 2021;21(1):723.","journal-title":"BMC Infect Dis"},{"key":"2694_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12959-018-0172-6","volume":"16","author":"T Kato","year":"2018","unstructured":"Kato T, Matsuura K. Recombinant human soluble thrombomodulin improves mortality in patients with sepsis especially for severe coagulopathy: a retrospective study. Thromb J. 2018;16:19.","journal-title":"Thromb J"},{"key":"2694_CR29","doi-asserted-by":"publisher","first-page":"797932","DOI":"10.3389\/fmicb.2022.797932","volume":"13","author":"S Spoto","year":"2022","unstructured":"Spoto S, Daniel Markley J, Valeriani E, et al. Active surveillance cultures and procalcitonin in Combination with Clinical data to guide empirical antimicrobial therapy in Hospitalized Medical patients with Sepsis. Front Microbiol. 2022;13:797932.","journal-title":"Front Microbiol"},{"key":"2694_CR30","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2147\/IDR.S388438","volume":"16","author":"Z Li","year":"2023","unstructured":"Li Z, Zeng Q, Xu S, et al. Development and validation of a Nomogram for Predicting Tigecycline-related Coagulopathy: a retrospective cohort study. Infect Drug Resist. 2023;16:423\u201334.","journal-title":"Infect Drug Resist"},{"issue":"11","key":"2694_CR31","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1007\/s12035-020-02012-2","volume":"57","author":"N Sulimai","year":"2020","unstructured":"Sulimai N, Lominadze D. Fibrinogen and Neuroinflammation during Traumatic Brain Injury. Mol Neurobiol. 2020;57(11):4692\u2013703.","journal-title":"Mol Neurobiol"},{"issue":"9","key":"2694_CR32","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/jhbp.784","volume":"27","author":"S Uemura","year":"2020","unstructured":"Uemura S, Higuchi R, Yazawa T, et al. Level of total bilirubin in the bile of the future remnant liver of patients with obstructive jaundice undergoing hepatectomy predicts postoperative liver failure. J Hepatobiliary Pancreat Sci. 2020;27(9):614\u201321.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2694_CR33","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jiec.2021.03.035","volume":"98","author":"A Asif","year":"2021","unstructured":"Asif A, Park SH, Soomro AM, et al. Microphysiological system with continuous analysis of albumin for hepatotoxicity modeling and drug screening. J Ind Eng Chem. 2021;98:318\u201326.","journal-title":"J Ind Eng Chem"},{"key":"2694_CR34","doi-asserted-by":"publisher","first-page":"4949","DOI":"10.2147\/IDR.S339188","volume":"14","author":"YT Huang","year":"2021","unstructured":"Huang YT, Yu CI, Chen PY, et al. Comparison of bleeding risk between colistin-tigecycline and colistin-carbapenem treatment regimens: a retrospective cohort study. Infect Drug Resist. 2021;14:4949\u201355.","journal-title":"Infect Drug Resist"}],"container-title":["BMC Medical Informatics and Decision Making"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-024-02694-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12911-024-02694-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-024-02694-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T09:02:29Z","timestamp":1728032549000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedinformdecismak.biomedcentral.com\/articles\/10.1186\/s12911-024-02694-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2694"],"URL":"https:\/\/doi.org\/10.1186\/s12911-024-02694-x","relation":{},"ISSN":["1472-6947"],"issn-type":[{"value":"1472-6947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,4]]},"assertion":[{"value":"22 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with relevant laws and institutional guidelines and approved by the Ethics Committee of Sir Run Run Shaw Hospital (No. 2023\u2009\u2212\u20090518), affiliated with Zhejiang University School of Medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"284"}}